ERIE N2 UK LIMITED
Get an alert when ERIE N2 UK LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2027-09-30 (in 1y)
Last filed for 2025-12-31
Confirmation statement due
2026-11-05 (in 6mo)
Last made up 2025-10-22
Watchouts
None on the register
Cash
—
Latest balance sheet
Net assets
£17B
+5.2% vs 2024
Employees
—
Average over period
Profit before tax
£3B
+986.8% vs 2024
Net assets
2-year trend · vs Unclassified median
Accounts
2-year trend · latest reflected 2025-12-31
| Metric | Trend | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Turnover | — | — | |
| Operating profit | -£11,119 | -£9,637 | |
| Profit before tax | -£338,026,686 | £2,997,778,354 | |
| Net profit | -£338,026,686 | £2,997,778,354 | |
| Cash | — | — | |
| Total assets less current liabilities | £23,433,794,663 | £24,293,436,620 | |
| Net assets | £16,535,567,828 | £17,395,209,785 | |
| Equity | £16,535,567,828 | £17,395,209,785 | |
| Average employees | — | — | |
| Wages | — | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Return on capital employed | -0.0% | -0.0% | |
| Interest cover | -0.00x | -0.00x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- Mitchell Charlesworth (Audit) Limited
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“Thermo Fisher Scientific Inc. has indicated its intention to provide any necessary financial support to enable the company to continue in operational existence for the foreseeable future. To this extent, the directors have received a letter of support from Thermo Fisher Scientific Inc. confirming their financial support for a period of at least twelve months from when these financial statements are authorised for issue. Thus, the directors believe that it is appropriate for the financial statements to be prepared on the going concern basis.”
Group structure
- ERIE N2 UK LIMITED · parent
- Life Technologies Corporation 100%
- Thermo Fisher Scientific Powder Finance LLC 100%
- Thermo Fisher Scientific Powder Financing 2 LLC 100%
- Acoustic Cytometry Systems Inc 100%
- Affymetrix Inc 100%
- Affymetrix Japan KK 100%
- Ambion Inc. 100%
- Applied Biosystems LLC 100%
- Bender MedSystems GmbH 100%
- Biotrove Corporation 100%
- Biotrove International Inc 100%
- CellzDirect Inc 100%
- Combinati Incorporated 100%
- Compendia Bioscience Inc. 100%
- eBioscience Ltd 100%
- Gold Cattle Standard Testing Labs Inc 100%
- Invitrogen Argentina SA 99.82%
- Invitrogen BioServices India Pvt Ltd 99%
- Invitrogen Finance Corp. 100%
- Invitrogen IP Holdings Inc 100%
- Ion Torrent Systems Inc. 100%
- Kettlebrook Insurance Co Ltd. 67.5%
- Life Technologies Clinical Services Lab, Inc. 100%
- Matrix Microscience Inc 100%
- Molecular Probes Inc 100%
- NewcoGen PE LLC 100%
- Panomics LLC 100%
- Perbio Science Inc. 100%
- STC Biomanufacturing Inc 100%
- Thermo Fisher Israel Ltd 100%
- Thermo Fisher Scientific Colombia SAS 100%
- Thermo Fisher Scientific Life Technologies Israel Investment I Limited 100%
- Thermo Fisher Scientific Life Technologies Israel Investment II Limited 100%
- USB Corporation 100%
- Westover Scientific Inc 100%
Significant events
- “There were no adjusting events arising after the financial period.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
6 active · 4 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| OAKWOOD CORPORATE SECRETARY LIMITED | Corporate Secretary | 2018-10-23 | — | — |
| AHMED, Syed Waqas | Director | 2020-03-23 | Nov 1979 | British |
| CAMERON, Euan Daney Ross | Director | 2018-10-31 | Mar 1976 | British |
| GREEN, Georgina Adams | Director | 2024-04-18 | Mar 1970 | British |
| SMITH, Anthony Hugh | Director | 2018-11-12 | May 1962 | American |
| STARR, Alison Jane | Director | 2024-04-18 | Jan 1977 | British |
Show 4 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| GREGG, Rhona | Secretary | 2018-10-23 | 2026-03-31 |
| GRANT, Lucie Mary Katja | Director | 2018-10-23 | 2019-12-03 |
| INCE, Nicholas | Director | 2018-10-23 | 2018-11-01 |
| NORMAN, David John | Director | 2018-10-23 | 2024-04-18 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Invitrogen Europe Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2018-11-28 | Active |
Filing timeline
Last 20 of 35 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-05-04 | AA | accounts | Accounts with accounts type full | |
| 2026-04-01 | TM02 | officers | Termination secretary company with name termination date | |
| 2025-10-27 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-05-07 | AA | accounts | Accounts with accounts type full | |
| 2024-10-29 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-05-14 | AA | accounts | Accounts with accounts type full | |
| 2024-04-23 | AP01 | officers | Appoint person director company with name date | |
| 2024-04-19 | AP01 | officers | Appoint person director company with name date | |
| 2024-04-19 | TM01 | officers | Termination director company with name termination date | |
| 2023-10-24 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2023-05-17 | AA | accounts | Accounts with accounts type full | |
| 2023-01-27 | SH01 | capital | Capital allotment shares | |
| 2022-11-01 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2022-05-16 | AA | accounts | Accounts with accounts type full | |
| 2022-01-26 | SH01 | capital | Capital allotment shares | |
| 2021-10-29 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2021-09-14 | AA | accounts | Accounts with accounts type full | |
| 2021-07-14 | PSC02 | persons-with-significant-control | Notification of a person with significant control | |
| 2021-07-14 | PSC09 | persons-with-significant-control | Withdrawal of a person with significant control statement | |
| 2021-01-12 | SH01 | capital | Capital allotment shares |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 4
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2024 → FY2025 · period ending 2025-12-31 vs 2024-12-31
-
Turnover
—
Not reported
-
Cash
—
Not reported
-
Net assets
+5.2%
£16,535,567,828 £17,395,209,785
-
Employees
—
Not reported
-
Operating profit
+13.3%
-£11,119 -£9,637
-
Profit before tax
+986.8%
-£338,026,686 £2,997,778,354
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers